Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4700)	7/2/1998 12:48:00 PM
From: Zirdu	Read Replies (2) \| Respond to of 6136

Regarding Paine Webber biotech analyst Elsie Wang, I see in the June 30th Wall Street Journal, that she is rated at #1 of all biotech analysts for accuracy in earnings estimates, and #2 in stock picking skill. This is out of 26 or 27 biotech analysts in the survey. RR

To: Steve Fancy who wrote (4700)	7/2/1998 1:01:00 PM
From: Izzy	Respond to of 6136

AGPH stock price drop is certainly coming as a shock to me as I obviously expected the price to go up after the Geneva presentations. I have had a long talk this am with my broker, who tells me (again heresay) that Lind is in Geneva now and presumably is going to issue a "strong buy" on AGPH (? when) at the present price. I previously raised the issue about AGPH expending/investing so much money recently on other companies and the potential impact on upcoming and future earnings (no one replied). IMNR has also gone "south" today (amazing!) in spite of reasonably good Geneva reports. Isn't there another AIDS conference coming up? Just seems like today is not a good stock day (for the longs); even the internet stocks are down. Hopefully next wk will be better for AGPH/IMNR. Steve, what are the AGPH call options doing now? I'm tempted to go after some calls.